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PHeart Rhythm Disorders
Incidence of Stroke in Paroxysmal Versus
Sustained Atrial Fibrillation in Patients Taking
Oral Anticoagulation or Combined Antiplatelet Therapy
An ACTIVE W Substudy
Stefan H. Hohnloser, MD, FACC,* Dimitri Pajitnev, MD,* Janice Pogue, PHD,† Jeff S. Healey, MD,†
Marc A. Pfeffer, MD, FACC,‡ Salim Yusuf, MD, FACC,† Stuart J. Connolly, MD, FACC,†
for the ACTIVE W Investigators
Frankfurt, Germany; Hamilton, Ontario, Canada; and Boston, Massachusetts
Objectives Our goal was to determine the risk of stroke or non-cerebral embolism associated with paroxysmal compared
with sustained atrial fibrillation (AF).
Background The risk of stroke and non-cerebral embolism and the efficacy of oral anticoagulation (OAC) in paroxysmal AF as
compared with sustained AF are not precisely known.
Methods The ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) was a trial
comparing OAC to combined antiplatelet therapy with aspirin and clopidogrel for prevention of vascular events in
6,706 AF patients. The incidence of thromboembolic events and major bleeds were compared in patients with
paroxysmal AF (n  1,202) and persistent or permanent AF (n  5,495).
Results Patients with paroxysmal AF were younger, had a shorter AF history, more hypertension, and less valvular disease,
heart failure, and diabetes mellitus than patients with sustained AF. At baseline, patients with paroxysmal AF had a
CHADS2 (cardiac failure, hypertension, age, diabetes, stroke [doubled]) risk score of 1.79 1.03 compared with 2.04
 1.12 in patients with sustained AF (p 0.00001). The annualized risk of stroke or non-central nervous system
(CNS) systemic embolism was 2.0 in paroxysmal AF compared with 2.2 in sustained AF (relative risk 0.87, 95% confi-
dence interval [CI] 0.59 to 1.30, p  0.496). After adjusting for confounding baseline variables, the relative risk was
0.94 (95% CI 0.63 to 1.40, p  0.755). The incidence of stroke and non-CNS embolism was lower for patients
treated with OAC irrespective of type of AF. There were more bleedings of any type in patients receiving clopidogrel
plus aspirin, irrespective of the type of AF.
Conclusions Patients with paroxysmal AF treated with aspirin plus clopidogrel or OAC have a similar risk for thromboembolic
events than patients with sustained AF. This risk can be significantly lowered with OAC. (The ACTIVE W trial;
http://www.clinicaltrials.gov/ct/show/NCT00243178; NCT00243178) (J Am Coll Cardiol 2007;50:2156–61)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.076e
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ttrial fibrillation (AF) is associated with increased mortality
nd morbidity, mainly as a result of thromboembolic compli-
ations. Several risk stratification models of different complex-
ty have been introduced to identify AF patients who benefit
rom oral anticoagulation (OAC) (1). In none of these models,
he type of AF—paroxysmal versus persistent or permanent—
as emerged as an independent predictor of thromboembolic
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ccepted July 24, 2007.vents. The most recent guidelines on therapy of AF recom-
end the use of OAC, therefore, for patients with stroke risk
actors irrespective of the type of AF (2). However, this
ecommendation is based on relatively weak data. In fact, only
ne retrospective analysis has specifically addressed the risk of
troke in patients with paroxysmal versus chronic AF (3). This
tudy in 460 patients with paroxysmal AF who were enrolled in
he SPAF (Stroke Prevention in Atrial Fibrillation) trials
ound similar incidences of thromboembolic events for both
ypes of AF. This analysis was based on the SPAF trials
onducted more than 15 years ago and was limited to patients
reated with aspirin. The definition of “intermittent” AF as
sed by Hart et al. (3) is different from the definition of
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November 27, 2007:2156–61 Stroke in Paroxysmal AFaroxysmal AF as used in the current guidelines (2). More
mportantly, treatments for AF and for underlying cardiovas-
ular diseases have markedly changed, for instance regarding
herapy for arterial hypertension or current international nor-
alized ratio (INR) management. Finally, Hart et al. (3) used
nly data from patients treated with aspirin and not with
AC. Accordingly, a contemporary study is needed to confirm
he stroke risk of patients with paroxysmal as compared with
ustained AF. The present study, which is based on data from
,706 patients, enrolled in the largest AF trial completed
ACTIVE W [Atrial Fibrillation Clopidogrel Trial With
rbesartan for Prevention of Vascular Events]) aims to answer
questions: 1) in patients taking OAC or aspirin plus
lopidogrel, does paroxysmal AF carry a similar or lower stroke
isk compared with persistent or permanent AF? and 2) is there
difference in efficacy and safety of OAC or combined
ntithrombotic therapy using aspirin plus clopidogrel in pa-
ients with paroxysmal AF?
ethods
etails of the ACTIVE W study have been recently
ublished (4,5). In brief, patients with electrocardiograph-
cally documented AF and at least 1 risk factor for stroke
age 75 years; on treatment for hypertension; prior stroke,
ransient ischemic attack, or non-central nervous system
CNS] systemic embolus; left ventricular ejection fraction
45%; peripheral arterial disease; if patients were between
he ages of 55 to 74 years requirement to have either
iabetes mellitus requiring drug therapy or previous coro-
ary artery disease) were randomized to receive open-label
AC (target INR 2.0 to 3.0) or combined antiplatelet
herapy with aspirin (75 to 100 mg/day) and clopidogrel (75
g/day). The primary outcome of the main trial was the
rst occurrence of one of the following vascular events:
troke, non-cerebral systemic embolism, myocardial infarc-
ion, or vascular death. Major bleeding was the most
mportant safety outcome and was defined as any bleeding
equiring transfusion of at least 2 U of red blood cells or
quivalent of whole blood, or as bleeding associated with
eath, drop in hemoglobin of at least 5 g/dl, significant
ypotension with need of inotropic support, intraocular
leeding, bleeding requiring surgery, or symptomatic intra-
ranial hemorrhage. Patients were enrolled between June
003 and December 2004. In August 2005, the Data Safety
onitoring Board recommended stopping the ACTIVE W
tudy for strong evidence for superiority of OAC over the
ombined antiplatelet therapy.
ypes of AF. Patients were classified as having paroxysmal,
ersistent, or permanent AF (2,6) by local investigators.
atients with permanent AF had electrocardiogram-
ocumented AF at the time of enrollment and no
vidence of sinus rhythm in the 6 months before ran-
omization. Patients with paroxysmal or persistent AF
ay not have been in AF at the time of randomization,ut had electrocardiogram-documented AF on 2 separate
d
gccasions, at least 2 weeks
part, in the 6 months before
andomization.
tatistical analysis. Continuous
ariables were compared between
atients with paroxysmal versus
ersistent/permanent AF using
tudent t test. Because the
resent analysis aims to deter-
ine the thromboembolic risk
ssociated with the 2 specific
ypes of AF, the combination of
ll-cause stroke and non-CNS systemic embolism were
onsidered as the primary outcome variable. Total and
ajor bleeds were the main safety outcomes. Kaplan-Meier
urves were constructed for time to event and were com-
ared by log-rank tests before and after adjusting for
aseline variables. A 2-sided p value 0.05 was considered
tatistically significant.
esults
atient characteristics. A total of 6,706 patients were
andomized, of whom 1,202 (18%) had paroxysmal, 891
atients persistent, and 4,604 permanent AF. The 5,495
atients (82% of the entire study population) with persistent
r permanent AF were analyzed together as patients with
ustained AF. Patients with paroxysmal AF were younger,
ad a shorter history of the arrhythmia, more hypertension
s the underlying cardiovascular problem, and less valvular
isease, signs of heart failure, and diabetes mellitus com-
ared with patients with sustained AF (Table 1). The prior
aseline Characteristics of Patients Withroxysmal nd Sustained AF Treated With Aspirinlus Clopidogrel o OAC
Table 1
Baseline Characteristics of Patients With
Paroxysmal and Sustained AF Treated With Aspirin
Plus Clopidogrel or OAC
Paroxysmal AF
(n  1,202)
Sustained AF
(n  5,495) p Value
Age (yrs) 68.7 9.6 70.6 9.4 0.0000
Patients age 75 yrs 338 (28%) 2,004 (37%) 0.0000
Male gender 758 (63.1%) 3,665 (66.7%) 0.0159
Duration of AF by ECG
documentation
6 months 393 (32.7%) 972 (17.7%) 0.0000
6–24 months 265 (22.0%) 1,095 (19.9%) 0.0980
24 months 542 (45.1%) 3,423 (62.3%) 0.0000
Underlying CV disease
Hypertension 1,020 (84.9%) 4,489 (81.7%) 0.0092
CAD 355 (29.5%) 1,565 (28.3%) 0.3901
Prior MI 203 (16.9%) 959 (17.5%) 0.6402
Valvular disease 349 (29.0%) 1,865 (33.9%) 0.0011
CHF 220 (18.3%) 1,807 (32.9%) 0.0000
PAD 39 (3.2%) 195 (3.5%) 0.6030
Diabetes mellitus 217 (18.1%) 1,807 (32.9%) 0.0025
CHADS2 risk score 1.79 1.03 2.04 1.12 0.0000
F  atrial fibrillation; CAD  coronary artery disease; CHADS2  cardiac failure, hypertension, age,
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
CNS  central nervous
system
INR  international
normalized ratio
OAC  oral anticoagulation
RR  relative riskiabetes, stroke (doubled); CHF congestive heart failure; C
ram; MI myocardial infarction; OAC  oral anticoagulatioV cardiovascular; ECG electrocardio-
n; PAD  peripheral arterial disease.
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Stroke in Paroxysmal AF November 27, 2007:2156–61se of OAC was lower in paroxysmal AF (64.8% vs. 79.5%,
 0.00001) (Table 2). Patients with paroxysmal AF had
CHADS2 (cardiac failure, hypertension, age, diabetes,
troke [doubled]) risk score of 1.79  1.03 compared with
.04  1.12 in patients with sustained AF (p  0.00001).
able 3 shows that the lower mean CHADS2 risk score in
aroxysmal AF was due to younger age and the presence of
ess structural heart disease in these patients.
Patients were followed for median of 1.3 years until the
CTIVE W study was stopped after the recommendation
f the independent Data Safety Monitoring Board (5).
troke and non-CNS systemic embolism. In 1,202 pa-
ients with paroxysmal AF, 25 patients had strokes and 4
on-CNS systemic embolic events occurred compared with
36 and 20, respectively, in 5,495 patients with sustained
F. The annual rate of the combined end point of stroke or
on-CNS systemic embolism was 2.0 per 100 patient-years
n paroxysmal AF compared with 2.2 in sustained AF
relative risk [RR] 0.87, 95% confidence interval [CI] 0.59
o 1.30, p  0.50) (Fig. 1). After adjusting for prognosti-
ally important baseline variables (age, hypertension, heart
ailure, valvular heart disease, and diabetes mellitus), the RR
as 0.94 (95% CI 0.63 to 1.40, p  0.76) (Table 4). In the
ustained AF group, baseline CHADS2 risk score was 2.0
.1 in patients without compared to 2.7  1.3 in patients
ith subsequent stroke or systemic embolism (p  0.0001).
edications at Baseline
Table 2 Medications at Baseline
Paroxysmal AF
(n  1,202)
Sustained AF
(n  5,495) p Value
Antiplatelets/OAC
Aspirin 462 (38.4%) 1,421 (25.9%) 0.0000
Clopidogrel 59 (4.9%) 106 (1.9%) 0.0000
OAC 779 (64.8%) 4,367 (79.5%) 0.0000
ACE inhibitor 612 (50.9%) 3,012 (54.8%) 0.0140
ARB 181 (15.1%) 813 (14.8%) 0.8163
Beta-blocker 680 (56.6%) 3,157 (57.5%) 0.5764
Calcium-channel
blocker
361 (30.0%) 1,686 (30.7%) 0.6581
Antiarrhythmic drugs 530 (44.1%) 757 (13.8%) 0.0000
Digoxin 196 (16.3%) 2,254 (41.0%) 0.0000
Diuretic 520 (43.3%) 3,286 (59.8%) 0.0000
Statin 536 (44.6%) 1,992 (36.3%) 0.0000
CE angiotensin-converting enzyme; ARB angiotensin receptor blocker; other abbreviations as
n Table 1.
omponents of Baseline CHADS2 Risk Scores
Table 3 Components of Baseline CHADS2 Risk Scores
Paroxysmal AF Sustained AF p Value
Age 75 yrs 338 (28%) 2,004 (37%) 0.001
Hypertension 999 (83%) 4,450 (81%) 0.0536
Stroke/TIA/systemic
thromboembolism
170 (14%) 996 (18%) 0.3520
LV dysfunction 125 (10%) 996 (18%) 0.001
Peripheral arterial disease 33 (2.8%) 161 (2.9%) 0.7426
CHADS2 risk score 1.79 1.03 2.04 1.12 0.001pV  left ventricular; TIA  transient ischemic attack; other abbreviations as in Table 1.n paroxysmal AF, the respective numbers were 1.8  1.0
ersus 2.1  1.0 (p  0.066). There was no interaction of
F type and stroke/non-CNS embolism.
When the incidence of stroke and non-CNS systemic
mbolism was analyzed according to treatment allocation,
here were no significant differences in event rates between
atients with paroxysmal versus sustained AF (Table 4).
fficacy and safety of randomized therapy. The incidence
f stroke and non-CNS embolism was reduced by OAC in
atients with both types of AF (Table 4). For patients with
ustained AF, the RR for stroke or non-CNS systemic
mbolism was 2.09 for patients treated with aspirin plus
lopidogrel versus OAC (95% CI 1.50 to 2.93, p 0.0000).
or patients with paroxysmal AF, the RR was 1.61 (95% CI
.76 to 33.42, p  0.211) (Fig. 2). There was no significant
nteraction according to type of AF, indicating that OAC
educes stroke or non-CNS systemic embolism to a similar
xtent in both groups.
As detailed in Table 5, there was significantly more total
leeding in patients receiving therapy with clopidogrel plus
spirin, irrespective of the type of AF. The incidence of
ajor bleedings as defined per protocol was similar for both
reatment allocations.
iscussion
he present study is the largest to examine the incidence
f stroke and non-CNS embolism in patients with
aroxysmal compared with those with sustained AF and
n therapy with either OAC or clopidogrel and aspirin.
ata were obtained from the ACTIVE W study, the
argest single trial ever completed in AF comprising
,706 patients. The most important finding of the
Figure 1 Incidence of Stroke or Non-CNS
Systemic Embolism According to Type of AF
Cumulative hazard rates of stroke and non-central nervous system (CNS) sys-
temic embolisms in patients with paroxysmal (P) versus sustained (S) atrial
fibrillation (AF) treated with aspirin plus clopidogrel or oral anticoagulation.resent analysis is that paroxysmal AF carries the same
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November 27, 2007:2156–61 Stroke in Paroxysmal AFisk for thromboembolic complications as sustained AF.
his contemporary study thus confirms the only prior
tudy by Hart et al. (3) and results of a meta-analysis (7).
he second major finding is that therapy with OAC is
imilarly more effective compared with aspirin and clo-
idogrel in both forms of the arrhythmia.
isk of thrombolembolic complications related to type
f AF. Historical reports indicate that paroxysmal AF
ccounts for 35% to 66% of all AF (8), whereas newer
tudies using currently applied definitions of AF types found
hat approximately one-quarter of all AF is of the paroxys-
al type (9,10). In line with previous findings, ACTIVE W
Incidence of Stroke or Non-CNS Systemic EmbolisVersus Persis ent/Permanent AF Treated With
Table 4 Incidence of Stroke or Non-CNS SystVersus Persistent/Permanent AF Tr
Paroxysmal AF
(n  1,202)
n
Rate/100
Person-yrs
Overall
Stroke/non-CNS embolism 29 2.0
By treatment allocation:
clopidogrel and aspirin
Stroke/non-CNS embolism 18 2.4
By treatment allocation: OAC
Stroke/non-CNS embolism 11 1.5
*Adjusted for age, hypertension, heart failure, diabetes mellitus, valvu
CI  confidence interval; CNS  central nervous system; RR  rela
0.
0
0.
01
0.
02
0.
03
0.
04
0.
05
0.0 0.5 1.0 1.5
OAC
C+A
605 568 439 154
594 554 425 152
No. at Risk
OAC
C+A
Paroxysmal
Figure 2 Stroke and Non-CNS Systemic Embolism According to
Cumulative hazard rates of stroke and non-central nervous system (CNS) systemic
in patients with paroxysmal (left) versus sustained (right) atrial fibrillation. CA atients with paroxysmal AF were younger and had less
ssociated structural heart disease (i.e., valvular heart dis-
ase, congestive heart failure) compared with patients with
ustained AF. This suggests that patients with paroxysmal
F are at an earlier stage of the arrhythmia (i.e., less
lectrical and structural remodeling of the atria) and might
ave a lower risk for thromboembolic events (11). In fact,
he CHADS2 score was significantly lower in patients with
aroxysmal compared with those with sustained AF. De-
pite this, the risk of subsequent thromboembolic events was
imilar for ACTIVE W patients with both types of the
rrhythmia.
Patients With Paroxysmalin Plus Clopidogrel or OAC
Embolism in Patients With Paroxysmal
d With Aspirin Plus Clopidogrel or OAC
stained AF
 5,495) Paroxysmal Versus Sustained AF
Rate/100
Person-yrs RR 95% CI p Value
2.2 0.87 0.59–1.30 0.496
0.94* 0.63–1.40* 0.755*
3.0 0.79 0.48–1.30 0.346
0.84* 0.51–1.40* 0.509*
1.5 1.03 0.54–1.97 0.936
1.14* 0.59–2.20* 0.696*
ase.
; other abbreviations as in Table 1.
0 .
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Stroke in Paroxysmal AF November 27, 2007:2156–61Current guidelines recommendations on the use of OAC
n paroxysmal AF are based on weak data. Only 1 prior
tudy has aimed to evaluate the risk for thromboembolic
omplications depending on the type of AF. Hart et al. (3)
nalyzed the data from the SPAF I to III trials and found
imilar risk for patients with paroxysmal and sustained AF.
here are, however, several important differences between
his study (3) and the ACTIVE W study. First, more than
times as many patients with paroxysmal AF were enrolled
n our study than in all 3 SPAF trials. Second, in the SPAF
rials the diagnosis of “intermittent” AF required documen-
ation of sinus rhythm and of at least 2 AF episodes 3 to 12
onths before study entry (3). In contrast, the ACTIVE W
tudy relied solely on investigator-based definition of the
ype of AF. Third, the ACTIVE W study evaluated the risk
or thromboembolic complications in a population in which
he overall stroke risk on warfarin was much lower than in
revious studies. For example, the risk for ischemic stroke
nd non-CNS embolism on warfarin was 2.3% in the
PAF I trial (12) similar to risk for all-cause strokes plus
on-CNS embolism in warfarin-treated patients enrolled in
he SPORTIF III (Stroke Prevention Using the Oral Direct
hrombin Inhibitor Ximelagatran in Patients With Non-
alvular Atrial Fibrillation) trial (13). In contrast, the
ncidence of all-cause strokes plus non-CNS embolism was
uch lower in ACTIVE W patients on OAC (1.5% per
ear) similar to that observed in other recent anticoagulation
rials (i.e., 1.2% per year in SPORTIF V [14]). These lower
vent rates may reflect improvements in the management of
reatable stroke risk factors such as hypertension or heart
ailure along with better INR management. Thus, the
resent data represent the most up-to-date analysis of risk
or stroke and non-CNS embolism in patients with parox-
smal AF versus patients with sustained AF. Our findings
onfirm the observations made by Hart et al. (3) and provide
trong evidence that paroxysmal AF is risky, even if AF is
ot sustained. This may explain observations made in other
ontemporary trials such as AFFIRM (Atrial Fibrillation
ollow-up Investigation of Rhythm Management) (15). In
he AFFIRM trial, the prevalence of ischemic stroke was
.1% in patients in whom rhythm control was attempted
ompared with 5.5% in those who were randomized to rate
ffect of Allocated Treatment on the Incidence of Total and Majorleedings in P ients With Paroxysmal Versus Persistent/Permane
Table 5 Effect of Allocated Treatment on the Incidence of TotaBleedings in Patients With Paroxysmal Versus Persiste
Clopidogrel and Aspirin
Patients Events Rate/100 Person-yrs Patients
Total bleedings
Sustained AF 2,722 515 15.0 2,773
Paroxysmal AF 608 116 15.3 594
Major bleedings
Sustained AF 2,722 77 2.3 2,773
Paroxysmal AF 608 21 2.8 594
bbreviations as in Tables 1 and 4.ontrol. Based on the present data, it is possible that gpisodes of (asymptomatic) paroxysmal AF in the rhythm
ontrol arm for which patients did not receive anticoagula-
ion therapy may account for this finding.
The results from the ACTIVE W study allow no firm
onclusion as to what amount of paroxysmal AF increases
isk for stroke and non-CNS embolism to that associated
ith sustained AF. However, this issue is currently being
valuated in a prospective clinical trials (ASSERT [ASymp-
omatic atrial fibrillation and Stroke Evaluation in pace-
aker patients and the atrial fibrillation Reduction atrial
acing Trial]) in which pacemaker memory is used to
recisely determine the number of episodes and duration of
aroxysmal AF. This arrhythmia burden will be linked to
troke risk during 2.5 years of follow-up (16).
reatment effects. There is a relative paucity of data
erived from controlled clinical trials regarding the benefit–
isk ratio of OAC in patients with paroxysmal AF. From
he 5 primary prevention trials on OAC in AF, 2 enrolled
xclusively patients with permanent AF (17,18); in the
emaining 3 trials, the prevalence of paroxysmal AF was 7%
19), 16% (20), and 34% (12). Thus, before the ACTIVE
study, only data derived from meta-analysis indicated
hat aspirin was less effective in stroke prevention than
AC in patients with paroxysmal and sustained AF (21).
he present data demonstrate that the risk for stroke and
on-CNS embolism was significantly higher in patients
llocated to combined antiplatelet therapy compared to
AC. This also applied to patients with paroxysmal AF,
lthough due to the smaller sample size, the power to detect
reatment differences was somewhat smaller. The lack of a
ignificant interaction according to type of AF shows that
AC is equally effective in patients with paroxysmal com-
ared with those with sustained AF. Based on our data,
8 patients with sustained AF need to be treated with OAC
o prevent one thromboembolic event compared with 135
atients with paroxysmal AF.
tudy limitations. This study is not a natural history
aper. Thus, comparisons between stroke incidence of
atients with paroxysmal compared with sustained AF may
e confounded by the treatment variable. Accordingly, our
nalysis describes the outcomes of treated patients. It is
robably not correct to assume that paroxysmal AF is a
Major
ermanent AF
Anticoagulation
Clopidogrel and Aspirin
Versus Oral Anticoagulation Interaction
nts Rate/100 Person-yrs RR 95% CI p Value p Value
6 12.9 1.21 1.07–1.37 0.0032 0.5286
7 12.0 1.34 1.02–1.77 0.0386
9 2.0 1.14 0.82–1.58 0.4325 0.4380
3 3.2 0.88 0.49–1.60 0.6793nt AF
l and
nt/P
Oral
Eve
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2reater risk factor for stroke than sustained AF based on the
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November 27, 2007:2156–61 Stroke in Paroxysmal AFbservation that both types of AF have similar event rates,
lthough paroxysmal AF had a lower baseline CHADS2
isk score. This is because the study has much greater power
o detect a difference in CHADS2 score than to detect a
ifference in outcome rates.
onclusions
he present analysis of data obtained in the ACTIVE W
tudy, the largest trial on OAC in nonvalvular AF, convinc-
ngly demonstrates similar risks for stroke and non-CNS
mbolism in patients with paroxysmal compared with sus-
ained AF despite initially lower CHADS2 scores in the first
roup. In patients generally tolerant to OAC, this therapy is
ore effective than combined antiplatelet therapy, with
imilar risks for major bleeding events.
eprint requests and correspondence: Dr. Stefan H. Hohnloser,
. W. Goethe University, Department of Cardiology, Division of
lectrophysiology, Theodor-Stern-Kai 7, 60590 Frankfurt,
ermany. E-mail: Hohnloser@em.uni-frankfurt.de.
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